Yutaka Okawa

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells
    Tanyel Kiziltepe
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Mol Cancer Ther 6:1718-27. 2007
  2. pmc SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK
    Yutaka Okawa
    LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 113:846-55. 2009
  3. pmc Fatty acid synthase is a novel therapeutic target in multiple myeloma
    Yutaka Okawa
    LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Br J Haematol 141:659-71. 2008
  4. doi request reprint p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications
    Kenji Ishitsuka
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Br J Haematol 141:598-606. 2008
  5. pmc Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells
    Teru Hideshima
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 114:1046-52. 2009
  6. pmc PI3K/p110{delta} is a novel therapeutic target in multiple myeloma
    Hiroshi Ikeda
    LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Harvard Medical School, Boston, MA, USA
    Blood 116:1460-8. 2010
  7. pmc Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications
    Teru Hideshima
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 113:5228-36. 2009
  8. pmc MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts
    Sonia Vallet
    Jerome Lipper Multiple Myeloma Disease Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Blood 110:3744-52. 2007
  9. doi request reprint The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo
    Hiroshi Ikeda
    Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 15:4028-37. 2009
  10. ncbi request reprint Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells
    Teru Hideshima
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Br J Haematol 138:783-91. 2007

Detail Information

Publications17

  1. ncbi request reprint 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells
    Tanyel Kiziltepe
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Mol Cancer Ther 6:1718-27. 2007
    ..Taken together, these data provide the preclinical rationale for the clinical evaluation of 5-azacytidine, alone and in combination with doxorubicin and bortezomib, to improve patient outcome in MM...
  2. pmc SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK
    Yutaka Okawa
    LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 113:846-55. 2009
    ..Taken together, our data provide the framework for clinical studies of SNX-2112 to improve patient outcome in MM and other hematologic malignancies...
  3. pmc Fatty acid synthase is a novel therapeutic target in multiple myeloma
    Yutaka Okawa
    LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Br J Haematol 141:659-71. 2008
    ..This report demonstrated that inhibition of FAS has anti-tumour activity against MM cells, suggesting that it represents a novel therapeutic target in MM...
  4. doi request reprint p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications
    Kenji Ishitsuka
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Br J Haematol 141:598-606. 2008
    ..These results suggest that LY represents a promising novel targeted approach to improve MM patient outcome both by enhancing the effect of bortezomib and by reducing osteoskeletal events...
  5. pmc Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells
    Teru Hideshima
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 114:1046-52. 2009
    ..Moreover, IKKbeta inhibitors enhanced bortezomib-induced cytotoxicity. Our studies therefore suggest that bortezomib-induced cytotoxicity cannot be fully attributed to inhibition of canonical NF-kappaB activity in MM cells...
  6. pmc PI3K/p110{delta} is a novel therapeutic target in multiple myeloma
    Hiroshi Ikeda
    LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Harvard Medical School, Boston, MA, USA
    Blood 116:1460-8. 2010
    ..Our studies therefore show that PI3K/p110delta is a novel therapeutic target in MM and provide the basis for clinical evaluation of CAL-101 to improve patient outcome in MM...
  7. pmc Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications
    Teru Hideshima
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 113:5228-36. 2009
    ..Combination therapy targeting these kinases therefore represents a promising treatment strategy in MM...
  8. pmc MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts
    Sonia Vallet
    Jerome Lipper Multiple Myeloma Disease Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Blood 110:3744-52. 2007
    ..Our results therefore show novel biologic sequelae of CCL3 and its inhibition in both osteoclastogenesis and MM cell growth, providing the preclinical rationale for clinical trials of MLN3897 to treat OBD in MM...
  9. doi request reprint The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo
    Hiroshi Ikeda
    Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 15:4028-37. 2009
    ..We investigated the antitumor effect of murine/human chimeric CD138-specific monoclonal antibody nBT062 conjugated with highly cytotoxic maytansinoid derivatives against multiple myeloma (MM) cells in vitro and in vivo...
  10. ncbi request reprint Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells
    Teru Hideshima
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Br J Haematol 138:783-91. 2007
    ..These preclinical studies provide the framework for clinical trials of bortezomib with Perifosine to improve patient outcome in MM...
  11. ncbi request reprint BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth
    Hiroshi Yasui
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Br J Haematol 136:414-23. 2007
    ....
  12. doi request reprint High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties
    Samantha Pozzi
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Clin Cancer Res 15:5829-39. 2009
    ..The increasing incidence of osteonecrosis of the jaw and its possible association with high cumulative doses of bisphosphonate led us to study the effects of high doses of zoledronic acid (ZA) on bone remodeling...
  13. ncbi request reprint Successful combination therapy with trastuzumab and Paclitaxel for adriamycin- and docetaxel-resistant inflammatory breast cancer
    Yutaka Okawa
    Division of Hematology, Department of Internal Medicine, The Jikei University School of Medicine, 3 25 8 Nishishinbashi Minato Ku, Tokyo 105 846l, Japan
    Breast Cancer 11:309-12. 2004
    ..This report suggests that weekly combination therapy of trastuzumab and paclitaxel was useful for treatment of adriamycin-and docetaxel-resistant metastatic breast cancer...
  14. ncbi request reprint Purification and characterization of C-terminal truncated forms of histone H2A in monocytic THP-1 cells
    Jiro Minami
    Department of Biochemistry 1, Jikei University School of Medicine, 3 25 8, Nishishinbashi, Minato ku, Tokyo 105 8461, Japan
    Int J Biochem Cell Biol 39:171-80. 2007
    ..Our results suggest that histone H2A is cleaved at least at two sites by protease(s) that remain obscure, and might affect chromatins in the early stage of THP-1 cell differentiation...
  15. ncbi request reprint [Pulmonary cryptococcosis occurring 6 months after cladribine therapy for relapsed follicular lymphoma]
    Yutaka Okawa
    Division of Hematology and Oncology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan
    Rinsho Ketsueki 47:650-5. 2006
    ..These findings suggest that it is very important to pay attention to any opportunistic infection such as pulmonary cryptococcosis...
  16. ncbi request reprint Long-term follow-up high-dose chemotherapy (drug-only program) followed by autologous stem cell transplantation for aggressive non-Hodgkin's lymphomas
    Noriko Usui
    Division of Hematology and Oncology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan
    Clin Lymphoma 6:31-6. 2005
    ..Mobilized peripheral blood stem cells were used mainly as a source for ASCT and were used based on collection rates of CD34 cells...
  17. ncbi request reprint [Progressive outer retinal necrosis in a patient with malignant lymphoma]
    Yutaka Takei
    Division of Hematology and Oncology, Department of Internal Medicine, Jikei University School of Medicine
    Rinsho Ketsueki 45:250-1. 2004
    ..Vitrectomy with silicone oil tamponade saved his final visual acuity. This unusual event might be related to rituximab causing deterioration of humoral immunity...